Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), being held December 10-13, 2024, in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic estrogen receptor positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
康涅狄格州纽黑文,2024年11月25日(GLOBE NEWSWIRE) -- arvinas公司(Nasdaq: ARVN) 今日宣布,包括临床数据在内的三份关于vepdegestrant的海报将于2024年12月10日至13日在德克萨斯州圣安东尼奥举办的2024年圣安东尼奥乳腺癌研讨会(SABCS)上展示。vepdegestrant是一种新型的调控蛋白质降解荷尔蒙受体(ER)的药物,由arvinas和辉瑞联合开发,用于治疗早期、局部晚期或转移性雌激素受体阳性/人表皮生长因子受体2(HER2)阴性(ER+/HER2-)乳腺癌患者。
Poster session details are as follows:
海报展览会详细信息如下:
Poster Title: Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, Plus Palbociclib in CDK4/6 Inhibitor-Resistant WT ER and ER Y537S Mutant Patient Derived Xenograft (PDX) Models
Poster Session 3 (ID: P3-01-16)
Date: Thursday, December 12
Time: 12:30 p.m. – 2:00 p.m. CT
海报标题: 评估Vepdegestrant, 一种PROTAC雌激素受体(ER)降解剂, 与CDK4/6抑制剂抗药性Wt ER和ER Y537S突变患者来源的异体移植模型(PDX)中Palbociclib的联合应用
海报会议3(ID: P3-01-16)
日期: 12月12日星期四
时间: 中部时间下午12:30 - 2:00
Poster Title: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results
Poster Session 4 (ID: P4-12-03)
Date: Thursday, December 12
Time: 5:30 p.m. – 7:00 p.m. CT
海报标题:Vepdegestrant,一种蛋白质降解靶向嵌合物(PROTAC)雌激素受体(ER)降解物,加上Abemaciclib用于ER-Pos/人类表皮生长因子受体2(HER2)阴性晚期或转移性乳腺癌:TACTIVE-U初期10亿阶段结果
海报会议4 (ID: P4-12-03)
日期: 12月12日星期四
时间:下午5:30 – 7:00中部时间
Poster Title: Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination with Cyclin Dependent Kinase (CDK)4/6 Inhibitors and Everolimus
Poster Session 4 (ID: P4-08-13)
Date: Thursday, December 12
Time: 5:30 p.m. – 7:00 p.m. CT
海报标题:评估CYP3A4介导的与Vepdegestrant联合使用时的药物相互作用风险,一种蛋白质降解靶向嵌合物(PROTAC)雌激素受体(ER)降解物,与Cyclin Dependent Kinase (CDK)4/6抑制剂和Everolimus联合使用
海报会议4 (ID: P4-08-13)
日期: 12月12日星期四
时间:下午5:30 – 7:00中部时间
For copies of the abstracts, please visit the official SABCS website here.
如需摘要的副本,请访问官方SABCS网站这里。
About Vepdegestrant
Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER positive (ER+)/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer.
关于Vepdegestrant
Vepdegestrant是一种正在研究中的口服可用的PROTAC蛋白质降解剂,旨在有针对性地靶向并分解雌激素受体(ER),用于治疗ER阳性(ER+/HER2-)乳腺癌患者。Vepdegestrant正在作为潜在独立治疗和作为针对 ER+/HER2-转移性乳腺癌的多种治疗方案的一部分进行开发。
In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits.
2021年7月,Arvinas宣布与辉瑞全球合作,共同开发和商业化vepdegestrant ;Arvinas和Pfizer将共同分享全球开发成本、商业化费用和利润。
The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy.
美国食品药品监督管理局(FDA)授予vepdegestrant单用疗法治疗曾接受内分泌治疗的ER阳性/HER2阴性转移性乳腺癌成年患者快速跟踪认证。
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X.
关于arvinas
arvinas(纳斯达克:ARVN)是一家临床阶段的生物技术公司,致力于改善患有严重和危及生命的疾病的患者生活。通过其PROTAC(PROteolysis TArgeting Chimera)蛋白降解平台,该公司正在开拓蛋白质降解疗法的发展,旨在利用人体天然蛋白质清除系统,选择性和高效地降解和清除导致疾病的蛋白质。Arvinas目前正在推进多个处于临床开发阶段的研究药物,包括针对局部晚期或转移性ER+/HER2-乳腺癌患者的vepdegestrant;针对复发/难治性非霍奇金淋巴瘤患者的BCL6的ARV-393;以及针对神经退行性疾病中LRRK2的ARV-102。Arvinas总部位于康涅狄格州纽黑文。有关Arvinas的更多信息,请访问其网站,并在LinkedIn和X上关注。
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential of vepdegestrant as a monotherapy and as part of combination therapy to potentially treat patients with ER+/HER2- metastatic breast cancer. Statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "goal," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
前瞻性声明
本新闻稿包含根据1995年《私人证券诉讼改革法案》中定义的前瞻性声明,涉及辉瑞赛诺吉(vepdegestrant)作为单药或作为联合疗法的潜力,可能用于治疗ER+/HER2-转移性乳腺癌患者的声明。关于arvinas的策略、未来运营、未来财务状况、未来收入、预计成本、前景、计划和管理目标的声明都属于前瞻性声明。"预期,""相信,""估计,""期望,""打算,""可能,""或许,""计划,""预测,""项目,""目标,""潜力,""将,""可能,""应,""将继续"和类似表达旨在识别前瞻性声明,尽管并非所有前瞻性声明都包含这些识别词。
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: Arvinas' and Pfizer's performance of the respective obligations with respect to Arvinas' collaboration with Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other important factors discussed in the "Risk Factors" section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release.
arvinas实际上可能无法实现这些前瞻性声明中披露的计划、意图或期望,您不应过度依赖此类前瞻性声明。由于各种风险和不确定性,包括但不限于:arvinas和辉瑞就辉瑞与arvinas合作履行各自义务的表现;arvinas和辉瑞是否能够成功开展和完成vepdegestrant的临床开发;arvinas和辉瑞是否能够获得vepdegestrant的营销批准并按照现有时间表或完全商业化;arvinas保护其知识产权组合的能力;arvinas的现金及现金等价物资源是否足以支持其可预见和不可预见的营业费用和资本支出需求,以及在arvinas2023年12月31日结束的10-k表格中“风险因素”部分和美国证交会文件仓库中随后的其他报告中讨论的其他重要因素。本新闻稿中包含的前瞻性声明反映了arvinas对未来事件的看法,arvinas假设不会受适用法律的规定限制而更新任何前瞻性声明。不应依赖这些前瞻性声明来代表arvinas在本公告发布日期之后的任何日期的观点。
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
联系方式
投资者:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
媒体:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com